Quarterly report
Open the filing on sec.gov
VivoSim Labs, Inc. (VIVS)
Nasdaq: VIVS · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2010
The companyfiscal 2026, as filed
Revenue$131,000-9.0%
Net income-$13.8M-456.4%
Earnings per share$-5.35-214.7%
Operating cash flow-$10.8M-14.4%
Cash$5.0M-55.6%
Debtn/a
Shareholders’ equity-$1.1M-110.5%
Shares, diluted2,588,327+76.8%
Return on equityn/a
The recordfrom its filings
Filings in 202639
Newest filingNov 12 · 10-Q
Annual reportJul 14, 2026
Quarterly reportNov 12, 2026
Next report due10-Q by Feb 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $135,000Net income -$10.3MCash from operations -$10.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Form PRER14A
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.